$ORKA -Wednush reiterates Oruka Therapeutics $165 target Outpeform -HC Wainwright maintains $1`20 target Buy - $OSPN -Rosenblatt downgrades OneSpan to Neutral from Buy on earnings outlook -Analyst Catharine Trebnick made the rating change ahead of the company’s third-quarter 2026 earnings report -Maintains $18 target investing.com/news/analyst-r…

$NYXH -Cantor lowers Nyxoah target to $3 from $6 Overweight - $ORCL -Bernstein reiterates Oracle Outperform rating on AI business clarity -The analyst expects the company to revise financial targets upward as revenue performance obligation growth has been strong over the past four quarters. -Maintains $325 target investing.com/news/analyst-r…

$MTCH -Cowen raises Match Group target to $52 from $45 Buy - $MTSI -Raymond James upgrades MACOM to Outperform from Market Peform -Analyst Melissa Fairbanks cited the stock’s recent decline as creating an opportunity, with shares down 30% since the beginning of October. -Sets $300 target investing.com/news/analyst-r…

$MSFT -Wells Fargo reiterates Microsoft $725 target Outperform - -Raymond James raises Microsoft target to $630 from $540 -Highlights Azure strength -Maintains Outperform rating ca.investing.com/news/stock-…

$ULBI $ENS EnerSys to Acquire Ultralife in a $320 Million All-Cash Transaction - Ultralife shareholders will receive $16.00 per share at closing, a 166% premium to its October 26, 2026 closing stock price. stocktitan.net/news/ULBI/ene…

$MRNA -William Blair downgrades Modernato Market Perform from Outperform - Cites valuation concerns ng.investing.com/news/stock-…

$MELI -BTIG reiterates MercadoLibre $2150 target Buy - -Citi upgrades to Buy from Neutral -Citi is betting the post-election selloff offers value despite 2027 margin concerns -Lowers target to $2050 from $2100 ad-hoc-news.de/boerse/news/u…

$LFTO -Wedbush initiates Liftoff Mobile coverage at Outperform -Rating based on a combination of AI growth prospects with discounted valuation -Sets $25 target finance.yahoo.com/technology…

$INCY -HC Wainwright reiterates Incyte $152 target Buy -BMO maintains $130 target Market Perform -Oppenheimer restates $120 target Outperform investing.com/news/analyst-r…

$IART -UBS lowers Integra Lifesciences target to $14 from $19 Buy - $IDXX -UBS lowers IDEXX Laboratories target to $627 from $670 Neutral - $IMNM -HC Wainwright reiterates Immunome $40 target Buy -Wedbush maintains $35 target Outperform

$HLNE -BMO lowers Hamilton Lane target to $95 from $116 Outperform - $HUBS -UBS raises HubSpot target to $310 from $290 Downgrades to Neutral from Buy -Citi raises target to $287 from $210 Neutral - $HWM -Citi reiterates Howmet Aerospace $329 target Buy

$GH -BTIG raises Guardant Health target to $210 from $195 Buy - $GLW -Citi lowers Corning target to $200 from $220 Buy - $GLXY -BTIG lowers Galaxy Digital target to $35 from $45 Buy -Chardan Capital maintains $35 target Buy

$FLXS -Freedom Broker raises Flexsteel target to $86 from $80 Hold - $FN -Needham lowers Fabrinet target to $500 fro $650 Buy - $FROG -KeyBanc reiterates JFrog Overweight rating on security demand -JFrog remains one of its highest conviction ideas this year -Maintains $114 target investing.com/news/analyst-r…

$EW -Cowen reiterates Edwards Lifesciences $104 target Buy - $FDX -Bank of America lowers FedEx target to $359 from $378 Buy - $FLEX -Bank of America lowers Flex target to $150 from $180 Buy - $FLUT -UBS lowers Flutter Entertainment target to $130 from $140 Buy

$NUWE Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology - The ULTRA-Peds Registry included 91 patients across seven hospitals; 62% weighed less than 10 kg, including 41 patients below 5 kg. - During Aquadex treatment, 87% survived their treatment course, and 86.5% of procedures were completed without interruption. - ~68% of cases with complete data lasted their planned treatment duration. - Most circuits ending early did so because of vascular access problems or clotting. - Nuwellis intends to use the evidence to support a proposed labeling expansion from patients weighing 20 kg and above to those weighing 5 kg and above, following a completed FDA pre-submission meeting. stocktitan.net/news/NUWE/nuw…

$F Ford’s $30K Fathom EV Can Double as a Home Power Generator - The forthcoming electric truck will be able to power a home when it’s linked to a power setup that’s expected to cost about $2300 extra. caranddriver.com/news/a74263…

$NXPI NXP Semiconductors surprises with Q3 sales but stock drops - Revenue up 19.3% year on year to $3.79 billion barchart.com/share/news/8486… via @Barchart

$ICLR ICON Reports Third Quarter 2026 Results - Gross bookings were $3,789 million, an increase of 26.9% on quarter three 2025, with cancellations of $639 million, resulting in net business wins of $3,150 million and a book-to-bill of 1.56x. - Backlog as of September 30, 2026 was $24.5 billion. - Revenue for the third quarter was $2,024.8 million, representing a decrease of 2.9% on quarter three 2025, or a decrease of 2.5% on a constant currency basis. - GAAP net income was $122.1 million, resulting in diluted earnings per share of $1.58 in quarter three 2026, compared to diluted earnings per share of $(3.67) in quarter three 2025. - Adjusted net income for the quarter was $205.8 million, resulting in adjusted diluted earnings per share of $2.66 compared to $3.20 per share in quarter three 2025. stocktitan.net/news/ICLR/ico…